West Pharmaceutical, US9523901012

West Pharmaceutical stock gains 2.57 percent before the bell

Published on 09/23/2026 at 03:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

At the close on September 22, 2026, West Pharmaceutical stock had gained 2.57 percent after a Morgan Stanley upgrade raised its price target to USD 400.

Reinraum-Fertigung von Vials, West Pharmaceutical, ISIN US9523901012
West Pharmaceutical (ISIN US9523901012) stellt in sterilen Reinräumen Vials und Elastomer-Verschlüsse für Injektionssysteme her, Illustration mit AI erstellt.

West Pharmaceutical stock closed at USD 371.08 on the Nasdaq on September 22, 2026, up 2.57 percent. The move followed a Morgan Stanley upgrade reported by Yahoo Finance.

September 22, 2026 after the upgrade

West Pharmaceutical Services, Inc. (ISIN US9523901012, Nasdaq: WST) rose 2.57 percent to USD 371.08 on the Nasdaq. Morgan Stanley raised its rating from Equalweight to Overweight and lifted its price target from USD 365 to USD 400, according to Yahoo Finance. The upgrade price target stood 7.8 percent above the September 22 close.

The broader market also advanced during the session. The S&P 500 gained 0.4 percent on September 22, 2026, while West Pharmaceutical added 2.57 percent on the same Nasdaq session.

Today before the open

Morgan Stanley's revised Overweight rating and USD 400 target remain the latest specifically reported analyst catalysts for the stock ahead of the September 23, 2026 session. Market coverage from Post-Gazette described the broader US market as near record levels as oil prices fell.

Disclaimer...

en | US9523901012 | WEST PHARMACEUTICAL | boerse | 70161335 | bgmi